1. Home
  2. IMRX vs JRI Comparison

IMRX vs JRI Comparison

Compare IMRX & JRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$4.56

Market Cap

340.7M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Real Asset Income and Growth Fund of Beneficial Interest

JRI

Nuveen Real Asset Income and Growth Fund of Beneficial Interest

HOLD

Current Price

$12.83

Market Cap

357.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMRX
JRI
Founded
2008
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
340.7M
357.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
IMRX
JRI
Price
$4.56
$12.83
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$17.20
N/A
AVG Volume (30 Days)
1.9M
147.5K
Earning Date
05-04-2026
01-01-0001
Dividend Yield
N/A
9.38%
EPS Growth
37.75
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.67
$11.67
52 Week High
$10.08
$14.37

Technical Indicators

Market Signals
Indicator
IMRX
JRI
Relative Strength Index (RSI) 40.58 49.20
Support Level N/A $12.76
Resistance Level $5.47 $13.23
Average True Range (ATR) 0.54 0.22
MACD -0.07 -0.01
Stochastic Oscillator 10.71 56.38

Price Performance

Historical Comparison
IMRX
JRI

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

About JRI Nuveen Real Asset Income and Growth Fund of Beneficial Interest

Nuveen Real Asset Income and Growth Fund is a closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.

Share on Social Networks: